Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

ChinaBio® Partnering Forum 2024: Top Five Risks and Opportunities to Watch in China Life Sciences in the Coming Year

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

In this session, we bring a panel of legal leaders to discuss topics to help life sciences companies navigate risks and identify opportunities. 

In this session, we present a panel to discuss topics that will help life sciences companies navigate risks and identify opportunities. You will hear insights from Morrison Foerster partners: Janet Xiao, an IP expert and head of the firm’s China Life Sciences group; Chuan Sun, who has extensive experience in life sciences M&A and licensing transactions; Rongjing Zhao, who is highly experienced in cross-border M&A transactions; and Chen Zhu, who has extensive experience advising on sanctions and export control issues. The panel will be moderated by MoFo associate Sarah Wang.<ul><li>Through much of 2024, we’ve witnessed the continued trends in cross-border out-licensing deals for Chinese life sciences companies. What are the Dos and Don’ts for companies out‑licensing and acquiring technology generated in China for the overseas market?</li><li>As companies are looking for strategic investments, what are the key considerations to strategically divest non-China assets to an overseas entity to release capital and maximize investment?</li><li>With the promulgation of China’s Personal Information Protection Law, Data Security Law, and the relevant implementation regulations (including the recent regulation on cross-border data transfer), how should life sciences companies navigate through and ensure compliance with these laws?</li><li>The regulatory glance has never been stricter for life sciences companies. What are the sanctions and export controls trends, and what are the potential implications of the BioSecure Act for MNCs and Chinese biotechnology companies? What are the mitigation strategies and measures companies should take?</li><li>Identifying and mitigating potential risks of patent infringement lawsuits continues to be a key topic for life sciences IP strategists.</li></ul>Find more about the <a href="https://informaconnect.com/chinabio-partnering/agenda/2/" target="_blank">event</a>.<hr>

ChinaBio® Partnering Forum 2024: Top Five Risks and Opportunities to Watch in China Life Sciences in the Coming Year

Sign Up

Chuan focuses his practice on cross-border M&A transactions; sophisticated technology, media, and telecom (TMT) transactions; and complex IP/commercial matters across Greater China.With 20 years of experience in both Asia and the U.S., Chuan regularly advises multinational corporations, state-owned enterprises, private companies, and PE/VC firms in complex cross-border M&A transactions, joint ventures, strategic alliances, and business separation transactions.Chuan also has significant experience in strategic corporate-commercial and technology transactions, including outsourcing, manufacturing, distribution, supply and franchising arrangements, and IP licensing arrangements across multiple industries. His TMT and IP regulatory experience includes telecommunications, e-commerce, internet, cyber security, data privacy, cloud computing, as well as telematics.Prior to joining MoFo, he worked in the Hong Kong office of a Magic Circle firm and the Chicago office of another leading international firm.Chuan co-authored the Hong Kong & mainland China chapters of Getting the Deal Through – Telecoms and Media, 2014, 2015 & 2016; the Hong Kong & mainland China chapters of Getting the Deal Through: Market Intelligence – Telecoms and Media, 2015; and the Hong Kong chapter of Sourcing World 2nd Edition 2015.Chuan is fluent in Mandarin and English.“Chuan Sun has a wealth of knowledge on his clients’ existing products and services offerings and a good understanding of what terms they are or are not willing to accept. This helps tremendously with contract negotiations.”“Chuan Sun has extensive experience in the technology space. Many other competitor firms in the technology space are not really pure IT lawyers, as they are more focus on privacy and trade marks or other related fields, as opposed to technology contracts such as SAP or Microsoft software license agreements. A normal general commercial lawyer would not be able to identify the same issues or raise the right questions, as they are not equipped with the technology know-how of the products and services, their benefits, and general industry standard terms and trending patterns in the market.” Legal 500 Asia Pacific 2020

孙川律师的执业领域集中在大中华区的跨境并购交易，复杂的技术、媒体和电信(TMT)交易以及复杂的知识产权/商务事宜。孙律师在亚洲和美国有19年工作经验，他经常代理跨国公司、国有企业、私人企业和私募股权/风险投资机构处理复杂的跨境并购交易、合资、战略联盟和业务拆分等交易。孙律师在战略性的公司商务和技术交易方面也拥有极为丰富的经验，包括外包、制造、分销、供应与特许经营安排，以及跨行业知识产权许可安排等。他在TMT和知识产权监管方面的经验包括电信、电子商务、互联网、网络安全、数据隐私、云计算以及车联网。在加入美富前，孙律师在一家 “魔法圈”律所(Magic Circle)的香港办事处和另一家领先的国际律所的芝加哥办事处工作。孙律师与他人合著了2014，2015和2016版《让交易推进下去––电信与媒体》(Getting the Deal Through – Telecoms and Media)中的香港和中国大陆章节，2015年版《让交易推进下去：市场情报––电信与媒体》(Getting the Deal Through: Market Intelligence – Telecoms and Media)中的香港和中国大陆章节，以及2015年《采购世界》第二版(Sourcing World 2nd Edition)的香港章节。2018年《亚太法律500强》指出“孙川律师十分高效、负责和实际。他非常擅长处理IT协议，包括软件许可和IT采购合同的相关事宜。他也十分善于处理跨境TMT交易。”孙律师精通普通话和英语。

Chuan Sun

Managing Partner, Shanghai

Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet’s clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals.Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients’ complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. As impressed clients noted to Chambers, “Janet’s work is thorough, polished and always of the highest caliber. She is well equipped to advise international clients on patent prosecution and strategy in the biotech industry, drawing on substantial technical knowledge.”Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She helps some of the world’s most-sophisticated biopharmaceutical companies and investors assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works regularly with patent litigators in the event of legal challenges by third-party competitors or vice versa, and she is frequently called upon to represent clients in litigation and post-grant proceedings.Janet is the Head of firm’s China Life Sciences Group and served as co-chair of the global Life Sciences Group from 2016 to 2019. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Chambers Global praises her as an outstanding IP lawyer “who is renowned for her work on IP issues concerning complex cross-border transactions, where she regularly advises Chinese clients.” In a recent edition of Chambers Global, a client says, “Janet . . . is very experienced in advising life sciences clients doing business in China and the US . . . She is highly responsive and always gives practical advice. Her IP expertise adds tremendous value to our business.”Since 2005, Janet has been actively involved in the leadership team of the Chinese-American Biopharmaceutical Society (CABS), a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011–2012 term. She is also a member of BayHelix, a nonprofit organization of Chinese heritage leaders in the global life sciences and healthcare fields.

肖荐（Janet Xiao）博士的业务侧重于为生命科学公司处理在全球范围内的专利采购、专利组合管理和战略策划事宜。肖博士服务的客户范围广泛，包括大型跨国生物制药公司，例如赛尔基因公司（Celgene）和基因泰克公司（Genentech），也包括全球范围的新兴创业公司。她经常就与各种技术有关的专利事宜向客户提供法律意见，其中涉及的技术包括抗体疗法、细胞疗法、纳米医学、基因疗法、给药系统、诊断和和营养学等。来自全球的创新者纷纷向肖博士寻求专利申请和专利战略的法律咨询，这一点也得到了《钱伯斯指南》的认可。她帮助客户开发和加强其复杂的专利组合，从而为客户实现最大的商业价值。在为制药行业的客户制定数十亿美元专利组合的战略方面，肖博士发挥着重要的作用。《钱伯斯指南》曾引用客户评价称，“肖博士是我曾合作过的律师当中知识最渊博、效率最高的一位律师。她能很好地将专利组合的历史信息用于全球专利申请问题上。”肖博士针对风险投资、技术交易、并购和生物医药产品的市场推广与生产许可事宜开展广泛的知识产权尽职调查审查工作。她协助世界上一些最成功的生物制药公司和投资者，为其产品开发和投资评估潜在风险，并制定先发制人的风险管理策略。她曾牵头处理过数百个知识产权尽职调查项目，并凭借自己对癌症免疫治疗、基因编辑、新一代测序、液体活检、抗体制造和医疗设备领域的专利方面的深厚知识而闻名。肖博士时常与专利诉讼律师合作，处理由第三方竞争者提出的法律质疑，或对第三方竞争者提出的法律质疑，她还经常受聘代表客户处理专利诉讼和授予后程序。肖博士是美富中国生命科学业务组主管，她曾在2016至2019期间担任美富全球生命科学业务组的联席主管。肖博士是全球为数不多的既拥有很强的全球战略性知识产权管理技能，同时又对中国和中国客户独特的知识产权问题具有深刻理解的知识产权律师之一，她一直是处理中美跨境交易和在中国境内经营中所涉知识产权问题的首选律师。《钱伯斯全球指南》称赞她是一位优秀的知识产权律师，“她因处理与复杂跨境交易有关的知识产权问题工作而知名，经常代表中国客户处理这方面的事宜” 。在近期一版《钱伯斯全球指南》中，某客户评价称，“肖博士在为于中国和美国开展业务的生命科学客户提供法律意见方面，有非常丰富的经验。她非常负责而且总是提供切实可行的法律意见。她在知识产权方面的专业意见为我们的业务增添了巨大价值。”自2005年以来，肖博士一直积极参与北美华人生物医药协会（CABS）的领导工作。该协会是一家非营利组织，致力于成为连接中美两国生命科学领域的纽带。肖博士在2011至2012年间担任该协会主席。她还是百华协会（BayHelix）的成员。百华协会是一家非营利组织，由全球生命科技和医疗保健产业领域的华人精英组成。

Janet Xiao

Partner

Rongjing has extensive experience advising private equity firms, institutional investors and major corporations on complex cross-border transactions, including control deals and leveraged buyouts, mergers and acquisitions, growth capital investments, spin-offs, and distressed M&A transactions. She primarily represents private equity funds on investments and acquisitions in China and the rest of Asia. She also advises clients on take privates of U.S.-listed companies and other U.S. public and private company M&A transactions. Rongjing works across a range of sectors, with a particular interest and focus in the technology sector. Prior to joining MoFo, Rongjing was a partner in a leading international law firm’s Hong Kong and Shanghai offices for several years. She is a native Mandarin speaker and fluent in English. <h4>Representative Matters</h4><h5>Private Equity Investments and Controlling/Buyout Transactions </h5><ul><li>The Carlyle Group <ul><li>in its leveraged buyout of HCP Packaging, a global designer and manufacturer of packaging containers for the beauty industry, from Baring Private Equity Asia. This transaction was included in “Deals of the Year 2022” by China Business Law Journal;</li><li>in its US$1.05 billion leveraged buyout of VXI Global Solutions, a U.S.-based multinational service provider with major operations in the United States, Southeast Asia, Europe, and China; </li><li>and Anchor Equity Partners in their respective investments in Airoha Technology Corp., a global leading communications solutions fabless integrated circuit design house based in Taiwan, majority-owned and controlled by MediaTek Inc. (TWSE: 2454);  </li><li>with CITIC Limited and CITIC Capital Holdings in the US$2.08 billion acquisition of the McDonald’s operations in China and Hong Kong and negotiation of a 20-year master franchise agreement―the largest McDonald’s franchise in the world; </li><li>in its US$150 million investment in OneSmart Education Group (NASDAQ: ONE); </li><li>in its pre-IPO investment in Neiwai Inc., a Shanghai-based lingerie retail group; and</li><li>in its RMB530 million investment in Beijing Ubox Technology & Trade Co., Ltd, a leading vending machine operator in China. </li></ul></li><li>Centurium Capital in its US$150 million pre-IPO investment in NTX Group, a global textile technology company.</li><li>China International Capital Corporation in its pre-IPO convertible bond investment of an auto finance company and the subsequent restructuring and litigation. </li><li>Clearlake Capital Group and its portfolio company Alkegen, one of the largest specialty materials platforms in the world, on its US$470 million partial tender offer in Luyang Energy-Saving Materials Co. Ltd., a Shenzhen Stock Exchange-listed company (SZSE: 002088). </li><li>Coatue Management in its investment in Niutron Technologies, AI Rudder Technologies, Rox (Cay) Holdings Ltd; and the US$700 million pre-IPO investment in Dingdong Maicai (NYSE: DDL).  </li><li>KKR in its US$645 million sale of MMI Holdings to a Chinese consortium and the subsequent restructuring to regain control. </li></ul><h5>Cross-Border/Public M&A Transactions  </h5><ul><li>Ocumension Therapeutics (HKSE: 1477) in its PIPE investment in Alimera Sciences, Inc., a U.S. pharmaceutical company (NASDAQ: ALIM). </li><li>Sea Limited (NYSE: SE) in its acquisition of Phoenix Labs, an acclaimed independent games development company based in Vancouver.</li><li>Vimicro International Corp (NASDAQ: VIMC) in its going-private transaction.</li><li>Webull Corporation in three rounds of equity financings and pre-IPO financing, which raised over US$460 million in total. </li></ul>

赵蓉婧律师为私募股权基金、机构投资者和大型企业提供建议，对处理复杂的跨境交易（包括控股交易和杠杆收购、并购、成长型资本投资、分拆和困境企业并购交易）拥有丰富经验。赵律师主要代表私募股权基金处理其在中国和亚洲其他地区的投资和收购交易，她还就美国上市公司的私有化和其他美国上市及私有公司涉及的交易为客户提供建议。赵律师的业务涵盖各类行业领域，其中尤其侧重于科技领域。在加入美富之前，赵律师曾在一家领先的国际律师事务所的香港和上海办事处担任合伙人数年。赵律师的母语为普通话，精通英语。<h4>具有代表性的交易</h4><h5>私募股权投资和控股/收购交易 </h5><ul><li>代表凯雷投资集团 <ul><li>处理其向霸菱亚洲投资基金对HCP Packaging公司进行的杠杆收购。HCP Packaging是一家美容行业包装容器的全球设计与制造商，该交易被《商法》杂志评为“2022年度交易”；</li><li>处理其以10.5亿美元对VXI Global Solutions进行的杠杆收购，该公司是一家美国跨国服务提供商，在美国、东南亚、欧洲和中国有大量业务；</li><li>处理其和Anchor Equity Partners分别投资达发科技股份有限公司的事宜。达发科技是一家全球领先的通信解决方案无晶圆厂集成电路设计公司，其总部位于台湾，由联发科技股份有限公司（台交所代码：2454）持有多数股权并控制；</li><li>处理其与中信股份有限公司和中信资本控股组成的联合投资团以20.8亿美元收购麦当劳中国内地和香港业务的事宜，以及关于有效期20年的特许经营主协议的谈判（是麦当劳在全球规模最大的特许经营权）；</li><li>处理其针对精锐教育集团（纳斯达克代码：ONE）的1.5亿美元投资；</li><li>处理其对中国内衣零售集团内外集团的上市前投资；以及</li><li>处理其针对中国领先的售货机经营商北京友宝科斯科贸有限公司的人民币5.3亿元投资。</li></ul></li><li>代表大钲资本处理其针对全球纺织技术公司NTX Group的1.5亿美元上市前投资。</li><li>代表中国国际金融股份有限公司处理其对一家汽车金融公司的上市前可转换债券投资以及此后的重组和诉讼事宜。</li><li>代表清湖资本集团及其投资组合公司奇耐亚太处理其以4.7亿美元对深圳证券交易所上市公司山东鲁阳节能材料股份有限公司（深交所代码：002088）的部分要约收购。奇耐亚太是全球最大的特种材料平台之一。</li><li>代表Coatue Management处理其对Niutron Technologies、AI Rudder Technologies、Rox (Cay) Holdings Ltd的投资，及其对叮咚买菜（纽交所代码：DDL）的7亿美元上市前投资。</li><li>代表KKR公司处理其以6.45亿美元将MMI Holdings公司出售给一个中国财团，以及其后为重获控股权进行的重组事宜。</li></ul><h5>跨国并购/上市公司并购交易 </h5><ul><li>代表欧康维视生物（港交所代码：1477）处理其对美国制药公司Alimera Sciences, Inc.（纳斯达克: ALIM）进行PIPE投资的事宜。</li><li>代表冬海集团（纽交所代码：SE）处理其收购总部位于温哥华的知名独立游戏开发公司Phoenix Labs。</li><li>代表中星微电子有限公司（纳斯达克代码：VIMC）处理其私有化交易。</li><li>代表微步集团 (Webull Corporation)处理其三轮股权融资和上市前融资事宜，共筹集超过4.6亿美元。</li></ul>

Rongjing Zhao

Chen is a partner whose practice focuses on government and internal investigations, cross-border enforcement matters and commercial litigation. He has extensive experience advising on U.S. economic sanctions, anti-money laundering, Foreign Corrupt Practices Act (FCPA), securities and accounting fraud, and related governance and corporate compliance issues. Chen also has extensive experience conducting compliance due diligence and designing compliance programs for clients in connection with private equity portfolio investments, M&A and IPO transactions. He also has experience in U.S.-based civil litigation involving Asia-based defendants. In addition, Chen frequently guides corporate and financial institutions clients through risk management issues associated with state secrecy, data privacy and cross-border data export control.His clients include major state-owned enterprises, multinational corporations and individuals from various industries including banking, pharmaceutical, technology, entertainment, insurance, consumer retail and hospitality, with a particular focus on China, Japan and Southeast Asia.Chen has been recognized as a Future Leader by Who’s Who Legal Investigations 2019 - 2022.Chen is a frequent presenter at legal conferences and client workshops relating to anti-corruption, economic sanctions and white-collar enforcement.Prior to joining Morrison Foerster, he worked in the Hong Kong and New York offices of a leading U.S. law firm. Chen is a native speaker of English and Mandarin. He is a Registered Foreign Lawyer with the Law Society of Hong Kong.

朱晨昊律师的执业重点为政府与内部调查、跨境执法事宜以及商业诉讼。他在针对美国经济制裁、反洗钱、美国《反海外腐败法》（FCPA）、证券和会计欺诈以及相关政府和公司合规问题提供法律意见方面拥有丰富的经验。朱律师在针对私募股权资产组合投资、并购和IPO交易为客户开展合规尽职调查以及设计合规计划方面拥有丰富的经验。他在处理涉及亚洲被告的美国民事诉讼事宜方面也具备经验。此外，朱律师亦经常协助公司和金融机构客户处理与国家机密、数据隐私和跨境数据出口管制有关的风险管理问题。朱律师的客户包括银行、医药、技术、娱乐、保险、消费品零售以及酒店业等多个行业的大型国有企业、跨国公司以及个人，其业务重点是中国、日本和东南亚地区。2019年 - 2020年《法律名人录》和2019年 - 2020年《全球调查评论》均将朱律师评为“公司调查领域的未来领袖律师”。朱律师是美富（国际）律师事务所的合伙人。在加入美富之前，朱律师在一家顶级美国律所的香港和纽约办事处任职。朱律师的母语是英文和中文。他是香港律师会的注册外国律师。

B. Chen Zhu

Sarah frequently advises clients in strategic corporate-commercial and technology transactions in the sectors of life science and TMT, including in-licensing, out-licensing, collaboration, and development agreements in various types of traditional and emerging technology offerings, including software-as-a-service, on-premises software, and technology services and maintenance, and in a broad range of pharmaceutical products and technologies, including biopharmaceutical drugs, immunotherapies, antibody therapeutics, and vaccines.Before joining MoFo, Sarah was an associate in the Shanghai office of an international law firm. She is fluent in English and Mandarin.<h4>Representative Experience</h4><ul><li>A leading healthcare investment firm’s portfolio company in its series of license-in and license-out deals concerning: (i) the development and option agreement and license agreement with a private biotechnological company in the North America for the development of lipid nanoparticles (LNP) formulations for delivery of mRNA and for the commercialization and manufacturing of the protein product and the vaccine product utilizing the LNP technology; and (ii) the licensing-out agreement with a Hong Kong listed company for the development and commercialization of the mRNA technology in Greater China.</li></ul><ul><li>Hangzhou DAC Biotechnology Co., Ltd. on its collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the development and commercialization of antibody drug conjugate (ADC) products.</li><li>Jiangsu Hengrui Medicine Co., Ltd. in its US$165 million exclusive license agreement with Novaliq GmbH, a German pharmaceutical company focusing on ocular therapeutics, to develop, manufacture and commercialize the innovative, water-free drugs NOV03 (perfluorohexyloctane) and CyclASol® for the treatment of dry eye disease in mainland China, Hong Kong, Macau and Taiwan.</li><li>A FinTech firm in the strategic partnership between a pan-Asia retailer and a Hong Kong bank to construct a new customer loyalty and reward program to replace the current co-branded credit card program on the market.</li><li>An automobile retailer that is a subsidiary of a multi-national dealership operator in its ERP software license and support agreement and the service agreement with a European multi-national software corporation, on the subscription of its core software products and technologies.</li></ul>

王家尧律师经常就生命科学以及科技、媒体和电信（TMT）领域战略性的公司商业交易和技术交易向客户提供咨询，包括协助客户编制被许可协议、对外许可协议、协作协议及开发协议，涉及各种传统及新兴技术产品和服务，包括软件即服务（SaaS）、本地部署软件以及技术服务和维护等，还涉及广泛的医药产品和技术，包括生物制药产品、免疫疗法、抗体疗法和疫苗等。在加入美富前，王律师是一家国际律所上海办事处的律师。她精通英语和普通话。<h4>具有代表性的项目 </h4><ul><li>代表某顶级医疗保健投资机构的被投资公司处理涉及下列事宜的系列被许可及对外许可交易：（1）代表某领先的生物医药公司就其与加拿大某生物公司签订开发和选择权协议以及对内许可协议提供法律服务，以开发用于传递mRNA的脂质纳米颗粒（LNP）配方，并对利用LNP技术的蛋白质产品和疫苗产品进行商业化和生产；以及（2）与某香港上市公司签订对外许可协议，以在大中华区对mRNA技术进行开发和商业化。</li></ul><ul><li>代表杭州多禧生物科技有限公司与强生公司旗下杨森制药生物科技公司达成合作和许可协议，用于抗体偶联药物（ADC药物）的开发与商业化。</li></ul><ul><li> 代表江苏恒瑞医药股份有限公司处理其与Novaliq GmbH（一家专注于眼部治疗的德国制药公司）的1.65亿美元独家许可协议，对创新型无水药物NOV03（全氟己内酯）和CyclASol®进行开发、生产和商业化，用于在中国大陆、香港、澳门和台湾地区治疗干眼症。</li></ul><ul><li> 代表一家金融科技公司处理其所属的泛亚洲零售商与一家香港银行的策略性合伙，订立新的老顾客奖励计划来取代目前市场上的联合品牌信用卡计划。</li></ul><ul><li> 代表一家国际汽车经销集团旗下的汽车零售商，处理其ERP软件许可证和支持协议及与一家欧洲国际软件公司的服务协议，以订阅模式付费使用其核心软件产品和技术。</li></ul>

ChinaBio® Partnering Forum 2024: Top Five Risks and Opportunities to Watch in China Life Sciences in the Coming Year

10 Sep 2024 1:30 PM - 2:30 PM HKT